Cardiff Oncology (CRDF) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to 9978.33%.
- Cardiff Oncology's EBIT Margin fell 23413600.0% to 9978.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 10719.56%, marking a year-over-year decrease of 39835700.0%. This contributed to the annual value of 7123.13% for FY2024, which is 21826000.0% up from last year.
- Cardiff Oncology's EBIT Margin amounted to 9978.33% in Q3 2025, which was down 23413600.0% from 12212.4% recorded in Q2 2025.
- In the past 5 years, Cardiff Oncology's EBIT Margin ranged from a high of 5333.17% in Q1 2024 and a low of 14964.86% during Q1 2022
- In the last 5 years, Cardiff Oncology's EBIT Margin had a median value of 8325.83% in 2024 and averaged 9522.92%.
- Per our database at Business Quant, Cardiff Oncology's EBIT Margin surged by 91873100bps in 2024 and then tumbled by -78613200bps in 2025.
- Over the past 5 years, Cardiff Oncology's EBIT Margin (Quarter) stood at 7162.41% in 2021, then fell by -2bps to 7337.5% in 2022, then increased by 10bps to 6623.08% in 2023, then fell by -26bps to 8325.83% in 2024, then fell by -20bps to 9978.33% in 2025.
- Its EBIT Margin stands at 9978.33% for Q3 2025, versus 12212.4% for Q2 2025 and 13194.5% for Q1 2025.